Two new antitumor drugs of Yasheng medicine have obtained clinical approval

It is reported that this is the first two clinical research approval documents of original new drugs approved by Taizhou pharmaceutical high tech Zone since its establishment It also marks that Taizhou takes the lead in overcoming the difficulty of "apoptosis" target in the country, develops new target anti-tumor drugs, and is expected to achieve industrialization in the short term, which will become one of the first drugs to be listed in the same field in the world It is also understood that the two original first-class new drugs developed by AXA have entered the phase of synchronous clinical research in the United States and Australia respectively In November this year, at an international cancer academic conference held in Spain, the representative of AXA disclosed the research data of the original target anti-tumor drug apg-1387 and another original new drug, which aroused the strong interest of the international famous pharmaceutical companies, marking that the original anti-tumor drug from China has been recognized by the international peers Dr Yang Dajun, chairman of Yasheng company, said that these new anti-tumor drugs are all new small molecule target anti-tumor drugs independently researched and developed by Yasheng company, with independent intellectual property rights, which can be widely used internationally There are essential differences between "apoptosis" target anti-tumor drugs and common chemotherapy anti-tumor drugs Target anti-tumor drugs can locate anti-cancer drugs on tumor molecules, directly interfere with the growth and proliferation of tumor cells, and finally make them die Compared with chemotherapy anti-tumor drugs and targeted anti-tumor drugs, the newly developed target anti-tumor drugs have more direct and obvious effects and are more selective, which will provide new ways and drugs for the treatment of clinical malignant tumors, and have significant social and economic significance News extension: Yasheng pharmaceutical's original new drug at-101 obtained the approval of Chinese clinical research In October 2014, Yasheng Pharmaceutical Co., Ltd owned the global intellectual property rights and independently developed the original class 1.1 new drug at-101, which was approved by CFDA with the approval number of 2014l01944 and 2014l01945, respectively This is the first small molecule anti-tumor drug approved by CFDA to enter the clinical stage and act on the new target Bcl-2 protein after the US FDA It is also the first small molecule anti-tumor drug approved by China Pharmaceutical city enterprises Take the first clinical research approval document of original new drugs Bcl-2 protein is one of the main members of tumor cell apoptosis regulator family Its high expression can induce the occurrence of leukemia, non-small cell lung cancer, breast cancer and other malignant tumors In 2014, bcl-2 protein was rated as one of the most valuable "TOP10" targets in the world and one of the three most valuable anti-tumor drug targets! At present, only Abbott's abt-199 and its homologues abt-263, AXA's at-101 and apg-1252 are several original drugs in the world According to the clinical research results reported by ASCO in 2014, bcl-2 target inhibitors can effectively inhibit the development of CLL, MCL and other lymphocytic tumors, especially for patients with high-risk obstinacy or difficult to treat, the partial and complete remission rates have reached a high level, which is the best clinical effect among these patients so far And safety At the same time, bcl-2 target inhibitor can be combined with traditional chemotherapy drugs and TiNi targeted anti-tumor drugs At-101 has carried out a number of phase II clinical studies in the United States, including the phase II clinical studies in Mayo clinical research center In 2013, doctors from the Norris cotton Cancer Center (NCCC) in the United States found that the combination of at-101 and navitoclax (the original drug developed by Abbott in phase II clinical, code: ABT-737) has the potential to effectively treat chronic lymphocytic leukemia (CLL), The study was published online in the May 3, 2013 issue of the journal leukemia This study is helpful to solve a basic problem in the treatment of chronic lymphoblastic leukemia At-101 is a new chemical structure drug, with 11 global invention patents for compound structure and use! It was selected as one of the top ten anticancer drugs in the cancer expert survey sponsored by the famous clinical expert group of Windover information The R & D of the project has also been supported by a number of science and technology plans, such as the "12th Five Year Plan" national major new drug creation science and technology major project, the "863" project in 2012, and the Jiangsu Science and technology innovation team The success of drug development will fill the gap in the field of Bcl-2 target in China, and it is expected to become one of the first batch of similar drugs to be listed in the world At the same time, the success of drug development will provide cancer treatment drugs with new mechanism of action for the clinic, and also provide new treatment schemes for the clinical tumor, which has significant social and economic significance! Yang Dajun, chairman of Jiangsu Yasheng Pharmaceutical Development Co., Ltd and special expert of national "thousand talents plan", said that Yasheng pharmaceutical Jiangsu Yasheng Pharmaceutical Development Co., Ltd focuses on original drug research and development, and has many years of experience in research and development of new anti-tumor drug targets and original small molecule targeted anti-tumor drugs     The company mainly aims at the research and development hotspot and development trend of new small molecule targeted anti-tumor drugs in the world, systematically carries out research on new targets such as apoptosis regulatory factors and apoptosis like regulatory factors, designs, selects, evaluates, optimizes and develops original small molecule targeted anti-tumor drugs with independent intellectual property rights, fills the gaps in domestic technology research and market products, and develops a series of original anti-tumor drugs Small molecule targeted anti-tumor drugs enter the international high-end pharmaceutical market The company has formed a number of core technologies in the field of drug design and Optimization Based on target protein structure, with more than 40 international invention patents, and has successfully developed a number of original small molecule targeted anti-tumor drugs (chemical 1.1) into preclinical research or international clinical research at different stages At present, the company has more than 50 researchers of all kinds, including 3 national experts selected in the "Thousand Talents Program" of the Central Organization Department, 7 high-level talents with many years of overseas original drug research and development experience, more than half of the company's master's and doctor's personnel, and more than 10 people with senior titles The company is undertaking a number of national and provincial science and technology projects such as the national "major new drug creation" science and technology major project, the National 863 plan, the international science and technology cooperation plan of the Ministry of science and technology, the innovation team plan of Jiangsu Province, the Key Laboratory of Jiangsu Province, and the science and technology support plan of Jiangsu Province.